Keep Informed on Legal and Compliance Developments Affecting Diagnostic Labs
Best practices and expert insight to help lab professionals comply with regulations and identify strategic trends in business and technology
Already a Subscriber? Log in Here
Lab Industry Advisor Subscription
Struggling with Staying Informed? In the fast-paced world of diagnostic medicine, staying updated with the latest legal, compliance, regulatory, and industry insights is crucial. Yet, finding reliable and comprehensive information can be overwhelming and time-consuming.
Lab Industry Advisor to the Rescue! Lab Industry Advisor provides comprehensive, up-to-date insights and analyses tailored to your needs. With expert commentary and actionable advice, you’ll stay ahead of the curve. No more sifting through endless sources—everything you need is right here!
Start your free trial today and see how Lab Industry Advisor can transform your approach. Get instant access to invaluable resources designed to keep you informed and competitive. Explore detailed reports, in-depth articles, and exclusive industry insights that help you make better decisions faster. Choose from three subscription levels tailored to fit your needs: Essential, Premium, and Elite.
Additional Business Intelligence Offerings
Clinical Diagnostics Insider
Keeps you up-to-date on new diagnostic tests, testing trends and opportunities, and emerging test technologies
Virtual Events & Webinars
Virtual events & webinars offer a variety of solutions and strategies for dealing with key issues labs face.
Lab Industry Advisor Subscriptions Include
Analysis and insight on key compliance, legal, and business developments affecting laboratories
- Updates on changes to regulations
- Healthcare-related laws
- FDA approvals
- Business deals in the diagnostics space, and more
Latest Articles
LDTs Rule Update: More Support for Legal Challenges Against FDA
Key clinical laboratory organizations file amicus brief, reiterating that the FDA is overstepping its authority, and its new rule would cause “irreparable patient harm”
New FDA LDTs Guidance Offers Useful Summary, But Questions Remain
Recently released document for small labs offers a more digestible version of the final rule requirements but still lacks key details
CMS Slated to Close Change Healthcare Payment Program
Program meant to ease cash flow disruptions experienced by some Medicare providers and suppliers due to the cyberattack will conclude in mid-July
Advancements in Antimicrobial Susceptibility Testing: Part 1
A brief overview of antimicrobial susceptibility testing, current methods used, and new methods on the horizon.
Polygenic Risk Scores: A Cardiovascular Conundrum
Polygenic risk scores may offer new screening and risk stratification options for cardiovascular disease—but how valuable are they?
Expert Q&A: Enhancing Clinical Labs through Advanced Data Analytics
Lisa-Jean Clifford of Gestalt Diagnostics, discusses key trends, challenges, and solutions in data analytics for clinical labs.
Lost Ground: Cancer Screening in the COVID-19 Era
A pandemic-related drop in cancer diagnoses could spell long-term trouble for patients and providers.
Patient-Centric Strategies for Labs: A Roadmap for 2024
Five strategies for lab leaders to focus on to tackle the challenges of today and ensure future success.
OSHA Citations for Hazardous Chemicals in Labs May Stem from Subpar Training
Standard 1910.1450 requires labs to have a chemical hygiene plan.
Laboratory Safety: A Universal Right
Approaching laboratory safety from a diversity, equity, inclusion, and accessibility perspective.
AI: With the Lab Every Step of the Way
Artificial intelligence models have a valuable role to play in each phase of the total testing process.
FDA Watch: Agency Opens New Pathway for STI At-Home Sample Collection Kits
With US STI cases continuing to climb to numbers not seen in decades, a recent FDA approval comes at an opportune moment.
Roche & Quest Establish Toeholds in Emerging Alzheimer’s Blood Testing Market
While Roche has an early lead, Quest recently made key moves to improve its position in the AD patient-initiated blood testing market.
